The property sector is seeing an influx of local and international capacity.
Australia’s insurance market is entering a softening phase as competition increases, particularly in property and financial lines, according to WTW’s latest Global…
Blog
-
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
SAN FRANCISCO, Oct. 30, 2025 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London.
- Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 – webcast to be available at 11:00 a.m. Greenwich Mean Time / 3:00 a.m. Pacific Time – link here
The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your Jefferies representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar’s pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer, in several ongoing clinical trials.
Nektar is headquartered in San Francisco, California. For further information, visit http://www.nektar.com and follow us on LinkedIn.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661For Media:
Jonathan Pappas
LifeSci Communications
857-205-4403
[email protected]SOURCE Nektar Therapeutics
Continue Reading
-
Eugenie, Beatrice to keep royal titles
Prince Andrew will soon simply be known as Andrew Mountbatten Windsor after the process to strip the disgraced brother of King Charles III of all of his royal titles began today, but his daughters will keep theirs.
The formal process to remove…
Continue Reading
-
Chronic Spontaneous Urticaria Linked to Increased Heart Disease Risk
Individuals diagnosed with
chronic spontaneous urticaria (CSU) are at a moderately increased risk of multiple cardiovascular diseases, with conduction disorders showing the most consistent and significant association, according to a study…Continue Reading
-
Mathematical Model Forecasts Diabetes Complications 15 Years Out, Confirms Legacy Effect of Early Control
Researchers at the University of Chicago have developed a comprehensive mathematical model that predicts diabetes complications up to 15 years in advance, offering clinicians a powerful new tool to understand how early treatment decisions shape…
Continue Reading
-
Cutting sleep drug usage among older adults could reduce falls, result in economic savings, study finds
(Photo: Cavan Images/Getty Images)
…
Continue Reading
-
Robert De Niro’s grandson: 5 indicted in connection to death
Five alleged drug dealers are facing felony charges for their involvement in the death of Leandro De Niro-Rodriguez, the grandson of acting legend Robert De Niro.
A federal grand jury in New York indicted the quintet on Tuesday, each on a…
Continue Reading
-
Is Peacock Stuck at 41 Million Subs Forever?
For Peacock, the magic number is 42,000,000. It’s also proven to be an elusive number.
For the entirety of 2025, Peacock has been stuck at 41 million subscribers. Though there has been ebbs and flows — per subscription-measurement firm…
Continue Reading
-
Tim Cook says more AIs are coming to Apple Intelligence
This isn’t the first time we’re hearing about third-party integrations, as Apple software SVP Craig Federighi said last year that the company “may look forward to doing integrations with different models like Google Gemini in the future.”
Continue Reading
COVID-19 During Pregnancy Linked to Higher Risk of Neurodevelopmental Disorders in Children
Children born to mothers who had COVID-19 while pregnant face an elevated risk of developmental disorders by the time they turn 3 years old, including speech delays, autism, motor disorders, and other developmental delays, according to new…
Continue Reading